A várható élettartam hosszabbodásával egyre gyakoribbak a különféle reumatológiai és onkológiai megbetegedések, amelyek csontszövődményeinek csökkentésére széles körben alkalmaznak különböző per os és intravénás antireszorptív hatású készítményeket (például biszfoszfonátok). Ezek a szerek jótékony hatásuk mellett súlyos szövődményeket is okozhatnak, ilyen például a ma még nem teljesen tisztázott patomechanizmusú állcsontnecrosis. A szerzők célja egy átfogó szakmai tájékoztatás nyújtása a gyógyszer indukálta állcsontnecrosis lehetséges megelőzéséről és terápiájáról. A szakirodalmi áttekintés alapján készült dolgozat azokat a szűrőmódszereket ismerteti (előnyeikkel és limitációikkal együtt), amelyek segítségünkre lehetnek a gyógyszer indukálta állcsontnecrosis korai detektálásában. A szerzők a legújabb sebészi és adjuváns terápiás irányvonalakat is ismertetik. Megállapítják, hogy a patomechanizmus ismeretének hiányában jelenleg még hatékony terápiás modalitás nem áll rendelkezésre, és hangsúlyozzák mind a prevenció, mind a terápia során az interdiszciplináris együttműködés szükségességét és annak fontosságát. Jelenleg ez tűnik a gyógyszer indukálta állcsontnecrosis elleni leghatékonyabb eszköznek. Or. Hetil., 2014, 155(49), 1960–1966.
Kerschan-Schindl, K., Patsch, J., Kudlacek, S., et al.: Measuring quality of life with the German Osteoporosis Quality of Life Questionnaire in women with osteoporosis. Wien. Klin. Wochenschr., 2012, 124(15–16), 532–537.
Wilson, S., Sharp, C. A., Davie, M. W.: Health-related quality of life in patients with osteoporosis in the absence of vertebral fracture: a systematic review. Osteoporos. Int., 2012, 23(12), 2749–2768.
Brozoski, M. A., Traina, A. A., Deboni, M. C., et al.: Bisphosphonate-related osteonecrosis of the jaw. Rev. Bras. Reumatol., 2012, 52(2), 265–270.
Ruggiero, S. L., Dodson, T. B., Fantasia, J., et al.: American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J. Oral Maxillofac. Surg., 2014, 72(10), 1938–1956.
Aghaloo, T. L., Felsenfeld, A. L., Tetradis, S.: Osteonecrosis of the jaw in a patient on Denosumab. J. Oral Maxillofac. Surg., 2010, 68(5), 959–963.
Serra, E., Paolantonio, M., Spoto, G., et al.: Bevacizumab-related osteonecrosis of the jaw. Int. J. Immunopathol. Pharmacol., 2009, 22(4), 1121–1123.
Otto, S., Schreyer, C., Hafner, S., et al.: Bisphosphonate-related osteonecrosis of the jaws – characteristics, risk factors, clinical features, localization and impact on oncological treatment. J. Craniomaxillofac. Surg., 2012, 40(4), 303–309.
Marx, R. E.: Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws. J. Oral Maxillofac. Surg., 2009, 67(5 Suppl.), 107–119.
Vescovi, P., Merigo, E., Meleti, M., et al.: Surgical approach and laser applications in BRONJ osteoporotic and cancer patients. J. Osteoporos., 2012, 2012, 585434.
Mawardi, H., Giro, G., Kajiya, M., et al.: A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J. Dent. Res., 2011, 90(11), 1339–1345.
Reid, I. R., Bolland, M. J., Grey, A. B.: Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone, 2007, 41(3), 318–320.
Wood, J., Bonjean, K., Ruetz, S., et al.: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther., 2002, 302(3), 1055–1061.
Schuiling, K. D., Robinia, K., Nye, R.: Osteoporosis update. J. Midwifery Womens Health, 2011, 56(6), 615–627.
Tolia, M., Zygogianni, A., Kouvaris, J. R., et al.: The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res., 2014, 34(1), 23–37.
Lee, J. J., Cheng, S. J., Jeng, J. H., et al.: Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck, 2011, 33(9), 1366–1371.
Orwoll, E. S., Scheele, W H., Paul, S., et al.: The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res., 2003, 18(1), 9–17.
Vescovi, P., Merigo, E., Meleti, M., et al.: Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int. J. Dent., 2014, 2014, 107690.
Andrews, E. B., Gilsenan, A. W., Midkiff, K., et al.: The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J. Bone Miner. Res., 2012, 27(12), 2429–2437.
Epstein, M. S., Wicknick, F. W., Epstein, J. B., et al.: Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2010, 110(5), 593–596.
Delanian, S., Porcher, R., Rudant, J., et al.: Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J. Clin. Oncol., 2005, 23(34), 8570–8579.
Tousoulis, D., Antoniades, C., Vassiliadou, C., et al.: Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur. J. Heart Fail., 2005, 7(7), 1126–1132.
Albertini, R., Villaverde, A. B., Aimbire, F., et al.: Anti-inflammatory effects of low-level laser therapy (LLLT) with two different red wavelengths (660 nm and 684 nm) in carrageenan-induced rat paw edema. J. Photochem. Photobiol. B, 2007, 89(1), 50–55.
Salate, A. C., Barbosa, G., Gaspar, P., et al.: Effect of In-Ga-Al-P diode laser irradiation on angiogenesis in partial ruptures of Achilles tendon in rats. Photomed. Laser Surg., 2005, 23(5), 470–475.
Nicola, R. A., Jorgetti, V., Rigau, J., et al.: Effect of low-power GaAlAs laser (660 nm) on bone structure and cell activity: an experimental animal study. Lasers Med. Sci., 2003, 18(2), 89–94.
Frozanfar, A., Ramezani, M., Rahpeyma, A., et al.: The effects of low level laser therapy on the expression of collagen type I gene and proliferation of human gingival fibroblasts (Hgf3-Pi 53): in vitro study. Iran. J. Basic Med. Sci. 2013, 16(10), 1071–1074.
Scoletta, M., Arduino, P. G., Reggio, L., et al.: Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed. Laser Surg., 2010, 28(2), 179–184.
Agrillo, A., Filiaci, F., Ramieri, V., et al.: Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur. Rev. Med. Pharmacol. Sci., 2012, 16(12), 1741–1747.
Freiberger, J. J., Padilla-Burgos, R., McGraw, T., et al.: What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J. Oral Maxillofac. Surg., 2012, 70(7), 1573–1583.
Mozzati, M., Gallesio, G., Arata, V., et al.: Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol., 2012, 48(5), 469–474.
Farrugia, M. C., Summerlin, D. J., Krowiak, E., et al.: Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope, 2006, 116(1), 115–120.
Damm, D. D., Jones, D. M.: Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays. Gen. Dent., 2013, 61(5), 33–38.
Hungarian Society of Oral and Maxillofacial Surgeons, Hungarian Society of Osteoporosis and Osteoarthrosis, Hungarian Society of Oncologists, Hungarian Rheumatology Association, Hungarian Society of Orthopedic: Bisphosphonate-induced jaw osteonecrosis prevention and treatment. [Magyar Arc-, Állcsont- és Szájsebészeti Társaság, Magyar Osteoporosis és Osteoarthrologiai Társaság, Magyar Onkológusok Társasága, Magyar Reumatológusok Egyesülete, Magyar Ortopéd Társaság: A biszfoszfonátok által indukált állcsont-osteonecrosisok megelőzése és kezelése.] Orv. Hetil., 2010, 151(4), 148–149. [Hungarian]
Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde: http://www.dgzmk.de/zahnaerzte/wissenschaft-forschung/leitlinien.html
Chubb, S. A.: Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin. Biochem., 2012, 45(12), 928–935.
Hodsman, A. B., Fraher, L. J., Ostbye, T., et al.: An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest., 1993, 91(3), 1138–1148.
Baim, S., Miller, P. D.: Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J. Bone Miner. Res., 2009, 24(4), 561–574.
Pellegrini, G. G., Gonzales Chaves, M. M., Fajardo, M. A., et al.: Salivary bone turnover markers in healthy pre- and postmenopausal women: daily and seasonal rhythm. Clin. Oral Investig., 2012, 16(2), 651–657.
Borromeo, G. L., Tsao, C. E., Darby, I. B., et al.: A review of the clinical implications of bisphosphonates in dentistry. Aust. Dent. J., 2011, 56(1), 2–9.
Lazarovici, T. S., Mesilaty-Gross, S., Vered, I., et al.: Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J. Oral Maxillofac. Surg., 2010, 68(9), 2241–2247.
Vincenzi, B., Napolitano, A., Zoccoli, A., et al.: Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J. Hematol. Oncol., 2012, 5, 56.
Ziebart, T., Pabst, A., Klein, M. O., et al.: Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin. Oral Investig., 2011, 15(1), 105–111.
Aragon-Ching, J. B., Ning, Y. M., Chen, C. C., et al.: Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest., 2009, 27(2), 221–226.
Pakosch, D., Papadimas, D., Munding, J., et al.: Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac. Surg., 2013, 17(4), 303–306.
Brozovic, S., Vucicevic-Boras, V., Mravak-Stipetic, M., et al.: Salivary levels of vascular endothelial growth factor (VEGF) in recurrent aphthous ulceration. J. Oral Pathol. Med., 2002, 31(2), 106–108.
Ng, P. Y., Donley, M., Hausmann, E., et al.: Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and in vitro studies. FEMS Immunol. Med. Microbiol., 2007, 49(2), 252–260.
Senel, F. C., Kadioglu Duman, M., Muci, E., et al.: Jaw bone changes in rats after treatment with zoledronate and pamidronate. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2010, 109(3), 385–391.
Norton, J. T., Hayashi, T., Crain, B., et al.: Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1. J. Immunol., 2012, 188(7), 2977–2980.
Citrin, D. E., Hitchcock, Y. J., Chung, E. J., et al.: Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies. Radiat. Oncol., 2012, 7, 64.
Korostoff, A., Reder, L., Masood, R., et al.: The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol., 2011, 47(4), 282–287.
Bagan, J., Sáez, G. T., Tormos, M. C., et al.: Oxidative stress in bisphosphonate-related osteonecrosis of the jaws. J. Oral Pathol. Med., 2014, 43(5), 371–377.